Sharechat Logo

FPH - Dividend Reinvestment Plan Strike Price and AUD FX Rate

Monday 8th July 2024

Text too small?

Auckland, New Zealand, 8 July 2024 - Fisher & Paykel Healthcare Corporation Limited advises that the strike price for the dividend reinvestment plan (DRP) operating in respect of the dividend payable on Wednesday 10 July 2024 has been set at NZ$28.9705 per share (after the application of a 3% discount). The strike price is calculated as the volume weighted average sale price for an ordinary share calculated on all price-setting trades of shares which took place through the NZX Main Board over a period of five trading days immediately following the dividend record date of 27 June 2024.

 

Shareholders who have elected to participate in the DRP reinvest their dividends to receive additional shares, rather than cash. The number of Fisher & Paykel Healthcare shares to which participants are entitled is calculated by multiplying the net dividend per share by the number of that participant’s participating shares and then dividing that number by the issue price of NZ$28.9705, rounded down to the nearest whole share. The DRP offer document setting out the terms and conditions of the plan and further details of its operations is now available on the company’s website at www.fphcare.com/drp.

 

The company also advises that the foreign exchange rate used for the payment of the dividend on 10 July 2024 to Australian investors in AUD has been set at 0.90954.

 

About Fisher & Paykel Healthcare

 

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

 

 

 



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors